95 related articles for article (PubMed ID: 11510498)
1. Stability of a cisplatin-chondroitin sulfate A complex in plasma and kidney in terms of protein binding.
Zhang JS; Shen-Feng MA; Suenaga A; Otagiri M
Biol Pharm Bull; 2001 Aug; 24(8):970-2. PubMed ID: 11510498
[TBL] [Abstract][Full Text] [Related]
2. Effects of a cisplatin-chondroitin sulfate A complex in reducing the nephrotoxicity of cisplatin.
Zhang JS; Imai T; Otagiri M
Arch Toxicol; 2000 Aug; 74(6):300-7. PubMed ID: 11005675
[TBL] [Abstract][Full Text] [Related]
3. Molecular-weight-dependent pharmacokinetics and cytotoxic properties of cisplatin complexes prepared with chondroitin sulfate A and C.
Zhang JS; Imai T; Suenaga A; Otagiri M
Int J Pharm; 2002 Jun; 240(1-2):23-31. PubMed ID: 12062498
[TBL] [Abstract][Full Text] [Related]
4. Toxicodynamic evaluation of a cisplatin-chondroitin sulfate complex using a perfused kidney and human proximal tubular cells.
Zhang JS; Kadowaki D; Nonoguchi H; Hirata S; Seo H; Imai T; Suenaga A; Giam Chuang VT; Otagiri M
Ren Fail; 2011; 33(6):609-14. PubMed ID: 21631182
[TBL] [Abstract][Full Text] [Related]
5. Local distribution into brain tumor and pharmacokinetics of 4-pyridoxate diammine hydroxy platinum, a novel cisplatin derivative, after intracarotid administration in rats with 9L malignant glioma: simultaneous brain microdialysis study.
Tokunaga Y; Nakashima M; Sasaki H; Tomiyama N; Nakashima MN; Ichikawa M; Kaminogo M; Shibata S
Biol Pharm Bull; 2000 Dec; 23(12):1491-6. PubMed ID: 11145184
[TBL] [Abstract][Full Text] [Related]
6. Effects of sodium thiosulfate on the pharmacokinetics of unchanged cisplatin and on the distribution of platinum species in rat kidney: protective mechanism against cisplatin nephrotoxicity.
Nagai N; Hotta K; Yamamura H; Ogata H
Cancer Chemother Pharmacol; 1995; 36(5):404-10. PubMed ID: 7634382
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy.
Yu H; Tang Z; Zhang D; Song W; Zhang Y; Yang Y; Ahmad Z; Chen X
J Control Release; 2015 May; 205():89-97. PubMed ID: 25529533
[TBL] [Abstract][Full Text] [Related]
8. In vitro characteristics and in vivo plasma disposition of cisplatin conjugated with oxidized and dicarboxymethylated dextrans.
Nakashima M; Ichinose K; Kanematsu T; Masunaga T; Ohya Y; Ouchi T; Tomiyama N; Sasaki H; Ichikawa M
Biol Pharm Bull; 1999 Jul; 22(7):756-61. PubMed ID: 10443480
[TBL] [Abstract][Full Text] [Related]
9. Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo.
Nagai N; Ogata H
Cancer Chemother Pharmacol; 1997; 40(1):11-8. PubMed ID: 9137523
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic evaluation of (glycolato-O,O')diammine platinum(II) in lung lymph in sheep.
Koizumi T; Kubo K; Shinozaki S; Koyama S; Amari T; Hayano T; Fujimoto K; Kobayashi T; Sekiguchi M; Sakai R
Jpn J Cancer Res; 1993 Apr; 84(4):468-73. PubMed ID: 8514614
[TBL] [Abstract][Full Text] [Related]
11. Spectroscopic studies of interactions of chondroitin sulfates with cisplatin.
Zhang JS; Anraku M; Kadowaki D; Imai T; Suenaga A; Odani A; Otagiri M
Carbohydr Res; 2011 Apr; 346(5):631-7. PubMed ID: 21324437
[TBL] [Abstract][Full Text] [Related]
12. Effects of disopyramide and verapamil on renal disposition and nephrotoxicity of cisplatin in rats.
Hanada K; Odaka K; Kudo A; Ogata H
Pharm Res; 1999 Oct; 16(10):1589-95. PubMed ID: 10554102
[TBL] [Abstract][Full Text] [Related]
13. Binding kinetics of tetrachloro-1,2-diaminocyclohexaneplatinum (IV) (tetraplatin) and cis-diamminedichloroplatinum (II) at 37 degrees C with human plasma proteins and with bovine serum albumin. Does aquation precede protein binding?
LeRoy AF; Thompson WC
J Natl Cancer Inst; 1989 Mar; 81(6):427-36. PubMed ID: 2918550
[TBL] [Abstract][Full Text] [Related]
14. In vitro cytotoxicity, pharmacokinetics and ex vivo pharmacodynamics of a new platinum compound, cis-malonato [(4R,5R-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclopentane] platinum (II).
Kim DK; Kim HT; Cho YB; Kim TS; Kim KH; Hong WS
Anticancer Res; 1996; 16(1):251-6. PubMed ID: 8615617
[TBL] [Abstract][Full Text] [Related]
15. Comparison of ethanol plasma-protein precipitation with plasma ultrafiltration and trichloroacetic acid protein precipitation for the measurement of unbound platinum concentrations.
Ma J; Stoter G; Verweij J; Schellens JH
Cancer Chemother Pharmacol; 1996; 38(4):391-4. PubMed ID: 8674165
[TBL] [Abstract][Full Text] [Related]
16. Quantitative determination of unchanged cisplatin in rat kidney and liver by high-performance liquid chromatography.
Hanada K; Nagai N; Ogata H
J Chromatogr B Biomed Appl; 1995 Jan; 663(1):181-6. PubMed ID: 7704209
[TBL] [Abstract][Full Text] [Related]
17. Magnesium co-administration decreases cisplatin-induced nephrotoxicity in the multiple cisplatin administration.
Saito Y; Okamoto K; Kobayashi M; Narumi K; Furugen A; Yamada T; Iseki K
Life Sci; 2017 Nov; 189():18-22. PubMed ID: 28864226
[TBL] [Abstract][Full Text] [Related]
18. Protection effects of Taurine supplementation against cisplatin-induced nephrotoxicity in rats.
Saad SY; Al-Rikabi AC
Chemotherapy; 2002 Mar; 48(1):42-8. PubMed ID: 11901256
[TBL] [Abstract][Full Text] [Related]
19. Alterations in Cisplatin Pharmacokinetics and Its Acute/Sub-chronic Kidney Injury over Multiple Cycles of Cisplatin Treatment in Rats.
Okada A; Fukushima K; Fujita M; Nakanishi M; Hamori M; Nishimura A; Shibata N; Sugioka N
Biol Pharm Bull; 2017; 40(11):1948-1955. PubMed ID: 29093343
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of nitric oxide synthase aggravates cisplatin-induced nephrotoxicity: effect of 2-amino-4-methylpyridine.
Saad SY; Najjar TA; Daba MH; Al-Rikabi AC
Chemotherapy; 2002; 48(6):309-15. PubMed ID: 12673106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
